Murat Sezgin1, Murat Bülent Rabuş2, Emre Selçuk3, Özge Altaş2, Sabit Sarıkaya2, Mehmet Balkanay4, Mehmet Kaan Kırali2. 1. Department of Cardiovascular Surgery, Tunceli State Hospital, Tunceli, Turkey. 2. Department of Cardiovascular Surgery, Istanbul Kartal Koşuyolu Yüksek Ihtisas Training and Research Hospital, Istanbul, Turkey. 3. Department of Cardiovascular Surgery, Muş State Hospital, Muş, Turkey. 4. Department of Cardiovascular Surgery, Yeni Yüzyıl University Medical Faculty, Istanbul, Turkey.
Abstract
BACKGROUND: In this study, we aimed to investigate frequency, patterns, etiologies, and costs of unplanned readmissions after left ventricular assist device implantation. METHODS: Between April 2012 and September 2016, 99 unplanned readmissions of a total of 50 consecutive bridge-to-transplant patients (45 males, 5 females; mean age 46.9±10.3 years; range, 19 to 67 years) who were successfully discharged after left ventricular assist device implantation were retrospectively analyzed. Patient demographic data, hemodynamic measurements before implantation, and readmissions after discharge were recorded. Hospitalizations due to major problems which were unable to be managed in routine outpatient clinic were accepted as unplanned readmissions. Survival analysis was performed. RESULTS: The readmission rate was 1.7 per year after discharge. Survival of patients who were readmitted within the first 90 days was found to be significantly lower than those without early readmission. The most common reasons of readmissions during follow-up were major infection (23.2%), neurological dysfunction (22.2%), cardiac causes (12.1%), bleeding (11.1%), and device malfunction (10.1%). Neurological dysfunctions (82,005 USD) and device malfunctions (73,300 USD) caused the highest economic burden. CONCLUSION: Among patients with a left ventricular assist device, hospital readmissions are common. Development of preventive strategies as well as effective treatment methods focused on longterm adverse events is critical to reduce the frequency and costs of hospital readmissions.
BACKGROUND: In this study, we aimed to investigate frequency, patterns, etiologies, and costs of unplanned readmissions after left ventricular assist device implantation. METHODS: Between April 2012 and September 2016, 99 unplanned readmissions of a total of 50 consecutive bridge-to-transplant patients (45 males, 5 females; mean age 46.9±10.3 years; range, 19 to 67 years) who were successfully discharged after left ventricular assist device implantation were retrospectively analyzed. Patient demographic data, hemodynamic measurements before implantation, and readmissions after discharge were recorded. Hospitalizations due to major problems which were unable to be managed in routine outpatient clinic were accepted as unplanned readmissions. Survival analysis was performed. RESULTS: The readmission rate was 1.7 per year after discharge. Survival of patients who were readmitted within the first 90 days was found to be significantly lower than those without early readmission. The most common reasons of readmissions during follow-up were major infection (23.2%), neurological dysfunction (22.2%), cardiac causes (12.1%), bleeding (11.1%), and device malfunction (10.1%). Neurological dysfunctions (82,005 USD) and device malfunctions (73,300 USD) caused the highest economic burden. CONCLUSION: Among patients with a left ventricular assist device, hospital readmissions are common. Development of preventive strategies as well as effective treatment methods focused on longterm adverse events is critical to reduce the frequency and costs of hospital readmissions.
Authors: Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Monica M Colvin; Mark H Drazner; Gerasimos S Filippatos; Gregg C Fonarow; Michael M Givertz; Steven M Hollenberg; JoAnn Lindenfeld; Frederick A Masoudi; Patrick E McBride; Pamela N Peterson; Lynne Warner Stevenson; Cheryl Westlake Journal: J Am Coll Cardiol Date: 2017-04-28 Impact factor: 24.094
Authors: Justin A Ezekowitz; Eileen O'Meara; Michael A McDonald; Howard Abrams; Michael Chan; Anique Ducharme; Nadia Giannetti; Adam Grzeslo; Peter G Hamilton; George A Heckman; Jonathan G Howlett; Sheri L Koshman; Serge Lepage; Robert S McKelvie; Gordon W Moe; Miroslaw Rajda; Elizabeth Swiggum; Sean A Virani; Shelley Zieroth; Abdul Al-Hesayen; Alain Cohen-Solal; Michel D'Astous; Sabe De; Estrellita Estrella-Holder; Stephen Fremes; Lee Green; Haissam Haddad; Karen Harkness; Adrian F Hernandez; Simon Kouz; Marie-Hélène LeBlanc; Frederick A Masoudi; Heather J Ross; Andre Roussin; Bruce Sussex Journal: Can J Cardiol Date: 2017-09-06 Impact factor: 5.223
Authors: Mark S Slaughter; Joseph G Rogers; Carmelo A Milano; Stuart D Russell; John V Conte; David Feldman; Benjamin Sun; Antone J Tatooles; Reynolds M Delgado; James W Long; Thomas C Wozniak; Waqas Ghumman; David J Farrar; O Howard Frazier Journal: N Engl J Med Date: 2009-11-17 Impact factor: 91.245
Authors: Suzanne V Arnold; Philip G Jones; Larry A Allen; David J Cohen; Timothy J Fendler; Jonathan E Holtz; Sanjeev Aggarwal; John A Spertus Journal: Circ Heart Fail Date: 2016-08 Impact factor: 8.790
Authors: Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer Journal: Eur Heart J Date: 2016-05-20 Impact factor: 29.983